

13 March 2018

SATIVA INVESTMENTS PLC

(“Sativa” or the “Company”)

### **Application for Admission to the NEX Exchange Growth Market**

The Board of Sativa, an Investment Vehicle, was established to identify investment opportunities in the Medicinal Cannabis sector in Canada, that are internationally recognised as having well-developed and reputable laws and regulations for the research and production of Medicinal Cannabis and that comply with the United Nation’s conventions on narcotics. The Company’s investment strategy will focus on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis.

The Company is pleased to announce that it has today applied for admission of its entire issued share capital of 404,900,000 ordinary shares of 0.25 pence each (“Ordinary Shares”), to trading on the NEX Exchange Growth Market (“NEX”). Admission is expected to take place on or around 29 March 2018.

The Company has net funds of £1,448,040 after all expenses pertaining to admission to NEX.

Sector classification:	Financial Services
Corporate adviser:	Peterhouse Corporate Finance Limited
Website:	<a href="https://sativainvestments.co.uk/">https://sativainvestments.co.uk/</a>
Company address:	85 Great Portland Street, London, W1W 7LD
Company telephone number:	+ 44 (0) 20 7971 1255

The Company has raised £1,000,000, conditional on Admission, pursuant to a Subscription.

All Shareholders and the subscribers to the Subscription Shares have undertaken with the Company and Peterhouse, not to dispose of any interest in the Ordinary Shares held by them for a period of 12 months following Admission in such manner as may reasonably be required without first consulting the Company and Peterhouse in order to maintain an orderly market in the shares.

### **Company Information**

The investment strategy of the Company is to provide Shareholders with an attractive total return achieved primarily through capital appreciation. The Directors believe that there are numerous investment opportunities within both private and public businesses in the Medicinal Cannabis sector in Canada that is internationally recognised as having, well-developed and reputable laws and

regulations for the research and production of Medicinal Cannabis and that comply with the United Nation's conventions on narcotics.

The Company is likely to be an active investor and acquire control of certain target companies although it may also consider acquiring non-controlling shareholdings. The proposed investments to be made by the Company may be in either quoted or unquoted securities and made by direct acquisition of an interest in companies, partnerships or joint ventures, or direct interests in projects and can be at any stage of development. Accordingly, the Company's equity interest in a proposed investment may range from a minority position to 100 per cent. ownership and a controlling interest.

The Directors and the Medicinal Cannabis Advisory Board believe that their broad, collective experience, together with their extensive network of contacts, will assist them in identifying, evaluating and funding suitable investment opportunities.

### **Details of Directors**

The full names of the Directors of the Company and positions are as follows:

#### **Jeremy Howard Prance Thomas, Chief Executive Officer (Aged 57)**

Jeremy is an entrepreneur with a successful track record in the telecommunication, e learning and consumer finance industries. Jeremy co-founded The Carphone Group Plc in the late 1980's and grew the business to exceed 10 per cent. of market share before selling it to Cable & Wireless for approximately £16 million. This was followed by the creation and listing of PNC Telecom Plc, a telecoms business that at its peak was valued at over £200 million. In 2001 Jeremy co-founded TMTI Ltd. TMTI Ltd is a profitable technical support business which works with major brands in enhancing the customer experience. Jeremy also founded George Banco Ltd in 2013, a consumer finance business, which was recently sold to Non Standard Finance Plc for approximately £53 million. Jeremy's other business interests include Carbon Managers Ltd, an environmental services consultancy company.

#### **Mark Blower, Executive Director (aged 49)**

Mark Blower, Chief Operating Officer, is an experienced finance professional, having spent the last 20 years actively overseeing the financial performance of over 70 UK small and medium-sized enterprises, with a particular focus on raising debt and private equity. He began his career in 1996 at the Investment Banking division of a large UK bank, before joining NM Rothschild in 2000. He then ran a highly successful leveraged debt team for another UK lending institution for five years before starting his Private Equity career in 2010. During his career to-date he has held a number of board positions, across a variety of sectors.

Mark is also a non-executive director of The Football Conference Limited, which manages the competition known as the National League and English professional and semi-professional football league. Mark is also the chairman of Macclesfield Town Football Club, which is a full-time professional football club playing in the National League in England.

#### **Noel Lyons, Non-Executive Director (aged 52)**

Noel started his career in the accounting profession and progressed from there to management and

director level within various organisations. He has worked for such companies as Amoco/BP, Coca Cola, Kentz Corporation Plc and Oilinvest International, and has worked in diverse locations such as Africa and the Middle East.

Noel has been involved in several listings on AIM and the NEX Exchange Growth Market in both a management and advisory capacity, including as co-founder and, initially, as a non-executive director of Karoo Energy plc. Noel has an MBA and masters in Accounting and Finance.

### **Medicinal Cannabis Advisory Board**

Brief biographical details of the individuals on the Medicinal Cannabis Advisory Board are set out below:

#### ***Dr. Stuart Ungar***, MB,BS,(U.Lond), MRCP(UK),MRCS(ENG)

After pursuing post-graduate studies in General Medicine and research in biochemical neuropsychopharmacology at The Royal Post-Graduate Medical School, Dr. Ungar was in practice as a General Physician at The Princess Grace Hospital. Jointly with Dr. Raymond Prudo, Dr. Ungar founded a start-up company, The Doctors Laboratory PLC, a general pathology laboratory, that introduced a new paradigm in service provision for clinicians and pharmaceutical organisations throughout the United Kingdom and abroad. During his tenure as Chairman and a Board Director The Doctors Laboratory PLC grew very substantially and was sold to Sonic Healthcare in 2002. Currently Dr. Ungar is a Director of a NASDAQ quoted biopharmaceutical company creating drugs for acute and chronic orphan inflammatory diseases by modulating one or both of the complement C5 and leukotriene pathways. Dr. Ungar is qualified in medicine, with additional qualifications in medical biochemistry at the Royal Free Hospital, London and was admitted as a member to The Royal College of Physicians. Dr. Ungar is a Life Fellow of The Royal Society of Medicine and is a founder and former Vice-President of The Independent Doctors Federation.

#### ***Dr. Peter Feldschreiber***

Dr. Feldschreiber is dually qualified as a barrister and physician. He specialises in medical and healthcare law including medical products liability, pharmaceutical and medical devices regulatory law, clinical negligence and personal injury and medically related employment litigation.

His casework includes the Aspirin Reyes Syndrome product liability litigation, Atomic Veterans Litigation, the morning after pill litigation, the Seroquel litigation, Foetal Anti- convulsant Syndrome Litigation, Cochlear Implants and Cardiac Stent Litigations and judicial review and references to the ECJ on pharmaceutical regulatory issues.

He has held appointments as Senior Medical Assessor and Special Litigation Coordinator to the Medicines and Healthcare products Regulatory Agency, Department of Health.

Dr. Feldschreiber is General Editor of The Law and Regulation of Medicines (Oxford University Press) and is Consultant Editor for the Volume on Medical Products for Halsburys Laws of England and the Lexis Nexis series on updates of UK and European Law. Dr. Feldschreiber is co-author of the chapter on the regulation of healthcare products in Butterworths Healthcare Law and Practice. Dr. Feldschreiber is also Visiting Senior Lecturer in Pharmaceutical Science at King's College London.

Dr. Feldschreiber is retained counsel to a number of solicitors and has experience of international litigation regarding drug induced injury. He has also published extensively on the law of causation and European regulatory procedure. Dr. Feldschreiber has published research into the repair of DNA

following ionising radiation whilst working at the Institute of Cancer Research. Dr. Feldschreiber is also a member of the Expert Witness Institute.

### ***Iqbal Gill***

Iqbal Gill is a chemist with 24 years of experience in the pharmaceutical, biotechnology, fine chemical and food sectors and, is currently Director of Research and Development at Tetralabs, a top-tier Medicinal Cannabis manufacturer located in the SF Bay Area in California. He directs the extraction and refinement of cannabinoids and other phytochemicals and their formulation into Medicinal Cannabis products. He has set up cGMP kilo lab and pilot facilities for the large-scale production of cannabinoids, analytical labs for QA/QC, and formulation labs, and is in charge of operations that produce, qualify and formulate hundreds of kilos pa of cannabinoids, and other phytochemicals. Iqbal Gill also oversees the isolation and characterisation of rare and novel cannabinoids, and the application of modern bio/chemical methods to cannabinoid drug discovery and drug targeting. He has also developed and owns a broad range of IP related to extraction, refinement, formulation, etc.

### **Directors' Interests**

On Admission the interests of the Directors and their immediate families and, so far as they are aware having made due and careful enquiries, of persons connected with them (all of which are beneficial, unless otherwise stated) (so far as is known to the Directors, or could with reasonable diligence be ascertained by them) (within the meaning of sections 252 to 254 of the UK Companies Act 2006) in the Issued Share Capital are and will be as follows:

<b><i>Director</i></b>	<b><i>Number of Ordinary Shares on Admission</i></b>	<b><i>% of Issued Share Capital</i></b>
Jeremy Thomas	224,000,000	55.32
Mark Blower	6,000,000	1.48
Noel Lyons	3,000,000	0.74

### **Significant Shareholders**

In addition to the Directors holdings disclosed above, as at 28 February 2018, the Company has been notified or is aware of the following holdings which will, following Admission, represent more than 3 per cent. of the Issued Share Capital or voting rights of the Company:

<b><i>Name</i></b>	<b><i>Number of Ordinary Shares on Admission</i></b>	<b><i>% of Issued Share Capital</i></b>
Andrew McDonald	18,000,000	4.45
Clive Lonsdale	18,000,000	4.45
James Curtis	18,000,000	4.45
Acqam International	18,000,000	4.45
George Thomas	18,000,000	4.45

--	--	--

For further information, please contact:

**The Company**

Noel Lyons

+ 44 (0) 20 7971 1255

**NEX Exchange Corporate Adviser:**

Peterhouse Corporate Finance Limited

Guy Miller/Mark Anwyl

+44 (0) 20 7469 0936